Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver

(2011) G. Targher et al.   DIABETIC MEDICINE

Effects of antidiabetic drugs in high-fat diet and streptozotocin–nicotinamide-induced type 2 diabetic mice

(2011) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms

(2011) Guiyuan Ji et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

(2011) Atsuo Tahara et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Inflammatory Markers Are Increased in Youth with Type 1 Diabetes: The SEARCH Case-Control Study

(2010) Janet K. Snell-Bergeon et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?*

(2010) Nicole S Glaser et al.   PEDIATRIC DIABETES

The geoepidemiology of systemic lupus erythematosus

(2009) Andrea T. Borchers et al.   AUTOIMMUNITY REVIEWS

Preventing hypoglycaemia: what is the appropriate glucose alert value?

(2008) P. E. Cryer   DIABETOLOGIA